• Articles
    • Views
    AUTHOR

    Samantha Freidin

    Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.

Author's Posts

  • Rhythm Biosciences’ colorectal cancer test outperforms the current gold standard, to hit market in 2022

    Despite a robust national cancer screening program, colorectal cancer remains the second most common cause of cancer death (after lung cancer) in Australia. Under the National Bowel Cancer Screening Program, Australians are invited to complete a faecal occult blood test to screen for the disease every two years from the age of 50-74. Evidence shows

    Read More
    Public
  • Whispir to scale globally with rising headcount following vaccination communications success

    In an age where we are bombarded with communications, companies need to stand out from the crowd. With an ever growing list of channels to connect through, companies need to adapt their messaging without compromising on clarity.  Enter Whispir (ASX: WSP), a global SaaS company providing communication solutions through their workflow platform. The Company expands

    Read More
    Public
  • Digital employee wellness platform experiences growth despite dwindling cash receipts

    Employee wellness has been at the forefront of employer’s minds since the pandemic pulled us out of the office and left us as tracksuit clad, makeup free recluses. At least in my case anyway.  Digital employee wellness company Limeade (ASX: LME) has seen organisation wide growth indicated by their increase in headcount and operating cash

    Read More
    Public
  • Can this biotech tap into a $183 billion market by buying time for stroke patients?

    Shareholders who took a punt on Argenica Therapeutics (ASX: AGN) when they made their market debut earlier this year will be pleased to read the Company’s roadmap to Phase 1 clinical trials.  The recently-listed Company has been subjected to the trials and tribulations of being listed, with a sharp sell-down post-IPO leaving their share price

    Read More
    Public
  • The meteoric rise of the meal kit thanks to a pandemic and a convenience economy

    The magic of click and collect and home delivered meal kits was around long before COVID-19 however, the pandemic has served as an undeniable accelerator to companies like My Food Bag (ASX:MFB), a New Zealand based meal kit delivery company. The Company creates and delivers meal kits with 98% NZ ingredients and simple recipe cards

    Read More
    Public
  • Resonating with investors – digital health company looking to turn themselves around

    Following months of a steadily downtrending share price, things seem to be looking up for digital health company Resonance Health (ASX: RHT).  Specialists in noninvasive medical imaging, the Company creates devices and software to aid in diagnosis and improve patient outcomes.  Having received regulatory approval in the USA, Europe and Australia, Resonance’s products are already

    Read More
    Public
  • Dosing commenced in Phase 2 trial for Pharmaxis’ lead asset myelofibrosis drug

    With a share price that has effectively doubled over the past few months and a drug pipeline beginning to snowball its successes, investors that identified Pharmaxis (ASX: PXS) early on are justifiably ecstatic. The clinical stage drug developers have had a strong start to FY22 with their lead asset, oncology drug PXS-5505 and anti-skin scarring

    Read More
    Public
  • Goodbye lounge room gym! Viva Leisure expands portfolio just in time for lockdown lift

    If you’re like me you’re probably a bit over using your lounge room as an office, cinema, dining room and gym. The multidisciplinary heart of my home is often littered with dumbbells, yoga mats, wine glasses and whatever book I’m currently reading. It’s an odd picture.  The thought of getting back into a real gym,

    Read More
    Public
  • ResApp expands their diagnostic offering into disease affecting 1 billion worldwide

    Experts estimate that sleep apnoea affects nearly 1 billion people worldwide. Every year, 4 million people die prematurely from chronic respiratory diseases such as COPD, asthma, acute respiratory tract infections, tuberculosis and lung cancer.  The global impact of respiratory based ailments is expansive, prompting The World Health Organisation to launch the Global Alliance Against Respiratory

    Read More
    Public
  • Contraceptive alternatives – Mayne Pharma receives FDA response putting them a step closer to approval

    Of the myriad of contraceptives out there, those that don’t require daily effort are gaining in popularity. As our lives get busier and brains get fuller, women are electing for long term, ‘set and forget’ birth control measures. Two thirds of Australian women of reproductive age use birth control. Whilst methods like the oral contraceptive

    Read More
    Public
  • Race Oncology gains more patents for their cancer drug, Zantrene

    The field of cancer research is certainly buzzing with key research yielding new medications with the ultimate goal of improving patient outcomes.  The mind numbingly broad list of diseases and disease subtypes that fall under the ‘cancer’ banner might make it seem like little to no progress is being made in conquering cancer. Look a

    Read More
    Public
  • Revolutionary cancer drug approved to commence Phase 2 clinical trials

    Clinical stage drug development company Pharmaxis (ASX: PXS) is one step closer to seeing their revolutionary cancer drug reach commercialisation. PXS-5505, the Company’s lead asset has received the go-ahead from the safety committee to begin Phase 2 trials following positive results from the Phase 1c study which saw patients with myelofibrosis treated for 28 days

    Read More
    Public
  • Could the milkman make a comeback? A case for reusables in food packaging

    Admittedly, the days of the milk man visiting, clanging glass bottles were well before my time. That being said, there’s something so wholesome and quaint about freshly delivered milk and bread in the morning. For those of a similar vintage to myself, here’s what would happen- the night prior to your milk delivery you’d leave

    Read More
    Public
  • Nest feathering Aussies propel Nick Scali to acquire Plush after strong pandemic earnings

    Cocktails are out, couches are in. Having become a mainstay of Saturday night lockdown plans, many Aussies have opted to upgrade their couch (and living room furniture), a trend serving to benefit furniture and homeware retailers. The niche market has reaped the rewards of Aussies feathering their nests in an effort to turn their space

    Read More
    Public
  • Prioritising employee wellness, how this fintech is making R&R the new R&D

    Organisational and personal development opportunities have largely fallen by the wayside for companies since the pandemic forced workers out of the office and into pyjama pants.  Logistical and technological barriers mean that it isn’t as easy as getting everyone into a room together for scheduled development programs, despite being an important part of business growth. 

    Read More
    Public
  • Chrome or Edge? Mac or Windows? Afterpay or Zip?

    The best tech often has a rival, another company doing similar work. Healthy competition puts consumers in prime position as companies battle it out to sweeten the deal and get you to hand over your precious cash.  iPhone people and Android people are almost two different social subclasses. So are sleek Mac users and practical

    Read More
    Public
  • Why this human dermatology company is now looking into treatments for dogs

    Pets are family. The staffy cross under my desk who lives here rent free will attest to that. Our fur children are exactly that, children. With little personalities, quirks, likes and dislikes it’s hard not to think of the four legged friend you share your space with as more than a dog.  Numerous studies have

    Read More
    Public
  • How to diversify your share portfolio

    “Don’t put all your eggs in one basket”. The simplest analogy and central thesis for why you should diversify your share portfolio, rewritten countless times in articles on the topic. You already know that investing is the key to building long term wealth. Establishing an investing strategy is important to help get you there; however,

    Read More
    Public
  • Body of evidence grows for Cynata’s stem cell production platform

    “Published” is an accolade that many scientists strive for. Showcasing your work and communicating your results to peers feels good, regardless of age.  The setting of scientific show and tell is within scientific journals, offering an enduring record of a scientist’s findings and impact on the world (vastly less obtrusive than being sat down and

    Read More
    Public
  • Has this medtech company created a new vital sign?

    Vital signs are important indicators of health, however, they often don’t show the whole picture. Technological advancements in the medtech world are equipping clinicians with valuable, detailed insights into their patients’ health, assisting with clinical decision making and optimising patient outcomes.  With over 700 devices in clinical use worldwide, Impedimed’s (ASX: IPD) clinically validated, fully

    Read More
    Public
  • Patent granted, share price up: Archer Materials reaches significant milestone

    Shareholders will be pleased to read that Archer Materials (ASX: AXE) has been granted a US patent for their 12CQ quantum computer chip.  The highly anticipated announcement comes after a media fumble last month that saw a popular Australian financial news masthead report several inaccuracies, prompting the Company to respond with a curt market release. 

    Read More
    Public
  • Top cosmetic dermatologist endorses Zelira’s cannabis-based acne treatment

    In 1964 Israeli chemist Raphael Mcechoulam boarded a bus to the Weitzman Institute in Rehovot with 5 kilos of hashish he received from the Israeli police. He used the material to isolate and identify THC, the psychoactive compound in cannabis. The discovery saw him crowned as “the father of cannabis research”.  Cannabinoid medicine specialist company

    Read More
    Public
  • Wellfully’s products expand into Russia, and my bathroom cupboard

    I am what my ex would call a ‘goop collector’.  This nickname was bestowed unto me due to my propensity to spend copious amounts of money on skincare products (goops), only to use half the bottle before finding something more exciting or more effective.  Honestly, looking at my bathroom cupboard makes me cringe at the

    Read More
    Public
  • Recognising the power of the female purse

    The ASX’s 2020 Investor Study details the lay of the land, revealing who is investing, when and how. The study reported that in the last two years there has been an influx of younger investors, approximately one quarter of recent new investors were between the ages of 18 and 24. The study also revealed that

    Read More
    Public
  • The OG OJ: Classic Aussie juice range gets a shake up

    Juice- both a Saturday morning staple and an adjunct to that near toxic tequila you got for your 18th.  Fruity beverage mogul Food Revolution Group (ASX: FOD) is helping keep those crappy tequila brands in the green with the expansion of their range of juices.  The Company plans to expand three products throughout the Coles

    Read More
    Public
  • This company turns bananas into sustainable food packaging

    With consumers becoming increasingly environmentally conscious, sustainable packaging is becoming the new norm.  Agricultural waste fibre technology company Papyrus Australia (ASX: PPY) has developed a zero-waste, chemical-free process of converting globally available agri-waste into usable products, thereby reducing the creation of methane and waste.  Where do they source this agri-waste? Bananas!  On average, one hectare

    Read More
    Public
  • EMVision is pioneering the next generation of stroke diagnosis

    It’s no secret that medical research and development is an expensive pursuit. Many medtech and pharmaceutical companies are constantly on the lookout for non dilutive funding to accelerate their projects, hopefully to market.  Medtech company EMVision (ASX: EMV) is focused on developing their portable medical imaging technology. The Company has secured access to $8 million

    Read More
    Public
  • Encouraging data for Orthocell biotech in pursuit of next gen ACL knee reconstructions

    The football player laying on the field clutching their leg might seem overdramatic until you read that the incidence of anterior cruciate ligament (ACL) tears is quite high – up to 10 injuries per 1,000 game hours, with the highest rates of injury reported in professional players.  Such an injury will sideline a player for

    Read More
    Public
  • Winning the war on talent: Setting the cultural standard for women in fintech

    Diversity and inclusivity in the workplace is increasingly important. More and more asset managers are looking at company environmental, social and governance (ESG) policies as a guidepost when making investment decisions. Both the technology and finance industries are among the least gender diverse. A recent study by Harvard Business Review revealed that only 30% ofRead More
    Public
  • Antimicrobial resistance at ‘tipping point’, threatening global food supply

    In a time where investors are more clued in than ever, environmental, social and corporate governance has become increasingly important. Whilst most companies simply check an ESG box, others go beyond and actively contribute to solving global challenges.  Last month the Global Leaders Group on Antimicrobial Resistance, an interagency group comprising experts from all overRead More
    Public
  • The medtech company looking to diagnose COVID by… sound…

    COVID-19 represents unchartered territory for everyone. Governments and various organisations across the globe have struggled to develop systems, policies and coordinate programs whilst researchers have scrambled to pull together clinically valid trials to deepen our understanding of our latest threat. ResApp (ASX: RAP) is a digital health company developing smartphone apps for both the diagnosis

    Read More
    Public
  • Acrux seeks FDA approval of generic acne treatment to disrupt $30 million market

    Mask-ne, iso skin, whatever the beauty blogs have dubbed it, acne sucks.  Yes, one of the many irritating side effects of this pesky pandemic is the resurgence of my teenage skin. Regular mask wearing and heightened stress has contributed to my new spotty appearance.  Sadly, my bathroom wouldn’t make for a very good “shelfie” these

    Read More
    Public
  • Pandemic presents opportunity for Aussie respiratory technology company

    I know, I know. We’re all sick of hearing news about the C word. Disgruntled Melbournians and aggrieved Sydneysiders aside, several companies are experiencing revenue boosting tailwinds from the pandemic situation. Respiratory technology company, Rhinomed (ASX: RNO) has received an initial purchase order from the Victorian Department of Health for one million Rhinoswabs to further

    Read More
    Public
  • FDA clearance received for yet another Adherium device

    Chronic respiratory disease is a growing concern, especially in the age of COVID-19, with a snowballing amount of studies examining the effects of ‘long COVID’- where symptoms persist long after the virus has cleared.  Medtech company Adherium (ASX: ADR) has what could be a very relevant and consequently very profitable suite of products designed to

    Read More
    Public
  • Digital healthtech 1st Group refreshes digital strategy to boost investor confidence

    Heeding the old adage “he who fails to plan, plans to fail”, digital health company 1st Group (ASX: 1ST) has shared their growth plans for FY22 with the market. With several brands already under their belt, the Company is building integrated platforms for online search and appointment booking services. Their flagship product, MyHealth1st is a

    Read More
    Public
  • Patents granted for Orthocell’s suture-less method of soft tissue repair

    The earliest known use of surgical sutures dates back to 3000 BC in ancient Egypt. Since then humans have experimented with sutures made from flax, cotton, hair, tendons, silk and anything vaguely thread-like. Taking surgical suturing to the next level is Orthocell (ASX: OCC), a Western Australian based company developing next-gen regenerative medicine products. The

    Read More
    Public
  • AnteoTech signs distribution rights in Turkey for their rapid COVID-19 test

    Companies the world over are pooling their strengths to address COVID-19, one of the most important global challenges of our time. Seeking to help in the field of rapid point of care testing, AnteoTech (ASX: ADO) is applying their proprietary technology to create the EuGeni COVID-19 Antigen Rapid Test.  The Company has signed a distribution

    Read More
    Public
  • How BCAL Diagnostics is improving minimally invasive methods of early cancer detection

    With 1 in 7 Australian women diagnosed with breast cancer, the demand for a minimally invasive, accurate diagnostic test is growing. Whilst health professionals recommend bi-annual breast screening for women aged 50-74, the invasive nature of imaging and ultrasound techniques leads to low compliance. There is well documented evidence that early cancer detection markedly improves

    Read More
    Public
  • Positive clinical trial results for nutritional shake bolsters $5m cap raise

    Days after raising $5 million via a capital raise to accelerate their global strategy, Nutritional Growth Solutions (ASX: NGS) has released clinical trial data showing positive results for their product Healthy Heights Grow Daily Boys 10+.  Just one of their growing range of products, Nutritional Growth Solutions creates clinically tested nutritional supplements for children, a

    Read More
    Public
  • 4DMedical’s clinical pilot program to progress following successful first phase

    Following a particularly well received first phase of their clinical pilot program, medical technology company 4DMedical (ASX: 4DX) is advancing their respiratory imaging platform to Phase 2 of their clinical pilot program. Conducted with Australia’s leading medical imaging provider, I-MED Radiology Network, Phase 1 of the program saw radiologists use 4DMedical’s proprietary XV Lung Ventilation

    Read More
    Public
  • A step closer towards scarless wound healing: Pharmaxis drug through Phase 1 trial

    Whilst key opinion leaders worldwide are following the Pharmaxis (ASX: PXS) story, Professor Fiona Wood has become an integral part of it.  Following the news out of Rochester University that their myelofibrosis drug, PXS-5505, has a potential significant disease modifying role in other cancers comes another key announcement for the company, this time regarding theirRead More
    Public
  • Rapid diagnostic kits drive Lumos revenue as FDA approval beckons for COVID tests

    Lumos Diagnostics’ (ASX: LDX) vision for decentralised diagnostic testing is slowly coming together with the Company releasing their full year results just one month after debuting on the ASX. Across the business, revenue increased 198% from FY20 to $25 million with its Commercial Services division the real MVP, delivering $22.7 million in revenue, a 188%

    Read More
    Public
  • Rhinomed puts new child-friendly COVID swab to the test

    Unless you’ve been living under a rock- we’re in a global pandemic. By now, you’ve probably had the pleasure of having your brain tickled through your nose via nasal swab, fretting that your annual winter cold is actually the plague.  Whilst most of us can handle the violation that is a nasal swab, testing children

    Read More
    Public
  • LiveTiles grows as employee experience becomes increasingly important

    With well over a year of working from home under our belts it’s safe to say that hybrid and remote work is no longer a temporary solution. Our new way of working has spurred the growth of some organisations providing solutions to enhance the digital working experience. LiveTiles (ASX: LVT) is one such company, creating

    Read More
    Public
  • Tackling the enduring epidemic taking place in the background of COVID-19

    With COVID dominating headlines for well over a year, you may not have noticed the worsening opioid crisis. Specifically in the United States where there has been a steep rise in overdose related deaths in the past 12 months. Data released by the National Centre for Health Statistics in July showed that in the year

    Read More
    Public
  • VEEM’s tech gets its sea legs with exceptional results in sea trials

    Think of VEEM Marine (ASX: VEE) as the team doing their best behind the scenes to make your experience better when lockdown ends and you finally board your yacht. Picture yourself: mimosa in hand, out on the ocean, enjoying the sun. Keeping that mimosa firmly in your hand and not spilled all over the deck

    Read More
    Public
  • ImpediMed receives FDA designation for dialysis device

    From the cochlear implant to pacemakers, medical devices have changed the way we treat and manage numerous conditions. Medtech company ImpediMed (ASX: IPD) saw a need in dialysis patients and sought to offer a better solution. Dialysis is the process of removal of water and waste products from the body to filter out toxins, and

    Read More
    Public
  • Quantum chips, biochips, hot chips, poker chips… Archer responds to media misgivings

    In a fumble of the facts, a popular Australian business masthead has been called out by one of the ASX’s hottest stocks over the past 12 months for factual errors in a piece yesterday titled “Archer Materials didn’t disclose Australian patent body’s objections”. The article made some market altering statements, publishing that Archer’s (ASX: AXE)

    Read More
    Public
  • Side hustle culture pushes Airtasker growth both locally and overseas

    With an ever growing side hustle culture and more time on our hands thanks to lockdowns, Airtasker (ASX: ART) is quickly becoming a household name.  The platform has claimed the title of Australia’s number one marketplace for local services. With their mission to empower people to realise the full value of their skills, more and

    Read More
    Public
  • Island Pharmaceuticals receives third patent for dengue fever drug

    Sorry COVID, there’s a slew of other diseases that require our attention as well. One of which is the highly contagious dengue fever. Joy. Transmitted by mosquitoes, dengue infects an estimated 390 million people each year. That number is set to rise as global warming sees mosquitoes travelling further than ever before. Treatment for those

    Read More
    Public
  • This ‘proptech’ is transforming the way we buy and sell homes

    Almost every industry has been forced to pivot and adapt to the increasingly digital world in the wake of COVID-19. Self proclaimed ‘proptech’, Openn Negotiation (ASX: OPN) offers a platform for the real estate industry to operate online. The Openn cloud-based software platform supports real estate agents to sell properties by facilitating negotiation, contracting and

    Read More
    Public
  • Cancer drug development company gathering momentum as more researchers worldwide take notice

    With promising data starting to flow from clinical trials, more and more medical researchers are tuning in to the Pharmaxis (ASX: PXS) story. The drug development Company has a diverse pipeline backed by solid science with drugs engineered by their world renowned drug development team. Lead drug candidate PXS-5505 is designed to treat myelofibrosis, aRead More
    Public
  • Blood test or crystal ball? Looking into the future of our health

    An estimated 1.2 million Australians are living with diabetes, a serious chronic disease with numerous complications and comorbidities including diabetic kidney disease (DKD). The risk factors for developing DKD are well known, but could we treat people better if we knew more about their personal risk factors, or predict the likelihood of future functional decline

    Read More
    Public
  • Austal – from where you’d rather be

    Your journalist would prefer to be on the sandy white beaches of Tahiti right now, sipping a cool mojito and sizzling in the sun.  But, with a long expired passport that won’t be renewed anytime soon, I’m bound to my inner city apartment.  Teasing me, and those locked down across the country is Austal Limited

    Read More
    Public
  • EMVision’s vision: Point-of-care diagnostic imaging for neurological conditions

    Time is of the essence when a stroke occurs. Each minute that a stroke patient goes without treatment, 1.9 million brain cells die. Early intervention is key and medtech company EMVision Medical Devices (ASX: EMV) wants to help get stroke treatment underway faster. Their point-of-care brain imaging platform allows for rapid diagnosis of neurological conditions

    Read More
    Public
  • Nutritional Growth Solutions reaching new heights with market expansion into China

    Nutritional Growth Solutions (ASX: NGS) is reaching new heights on their growth chart with expansion into global markets, confirming the launch of their proprietary Healthy Height® shake range in Chemist Warehouse in China. Addressing an overlooked subset of the nutritional supplement market, NGS creates clinically proven supplements to support healthy growth and development in children

    Read More
    Public
  • MDMA usage at University is through the roof as Emyria takes aim at mental health

    Harbouring more MDMA than music festival goers, the University of Western Australia (UWA) is leading the way in research around the use of MDMA as a psychedelic medication. Clinical drug development and care delivery company Emyria (ASX: EMD) has today announced a partnership with UWA, confirming access to their library of MDMA- like compounds developed

    Read More
    Public
  • Proteomics International to collaborate on world first blood test for endometriosis

    One in nine Australian women will suffer from endometriosis, a debilitating, chronic menstrual health disorder resulting in serious pain, fertility issues and reduced quality of life. The disease occurs when tissue similar to that within the lining of the uterus grows outside of the uterus in other areas of the body, commonly around the reproductive

    Read More
    Public
  • Aussie company SpaceLink to join the likes of Branson and Bezos

    In an age where CEOs can take to space in questionably shaped spacecraft, the demand for fast, reliable communications (so we can be reminded of how much money each minute burns) is growing. Electro Optic Systems (ASX: EOS) subsidiary company SpaceLink does just that. The Company has been selected by the Centre for the Advancement

    Read More
    Public
  • Identitii is dotting the i’s and crossing the t’s with their financial compliance tech

    You never forget your first, and neither will financial compliance tech company Identitii (ASX: ID8) which has hit the ground running with the newest fintech software, Overlay+, which has opened the door to a new stream of SaaS revenue.  The tech aims to simplify and automate financial crime compliance by making it easier to access

    Read More
    Public
  • Dosing complete, Pharmaxis progresses with skin scarring trials led by Professor Fiona Wood

    Our scars tell a story, whether it be grazed knees from the school yard or those mystery scrapes that make you wonder what on earth happened the night before.  More often than not these minor scars give us funny stories, laughs and reminders not to touch hot irons. But for more serious injury following events

    Read More
    Public
  • Looking to the future: Turning genetics into diagnostic tools for better health

    The one-size-fits-all approach to medicine is on its way out with the rise of personalised medicine. The development of technologies to individualise healthcare for each person holds much promise for tackling disease treatment and prevention. A prime example of this is the development of genetic testing for the BRCA genes. Inherited genetic mutations within these

    Read More
    Public
  • Hearing health to be prioritised under Government roadmap as Healthia expands into audiology

    The gaping dental shaped hole in the Australian healthcare system is a frequent point of contention and the more you look into it, the scope of Medicare coverage seems to narrow. Audiology is an essential service not entirely covered by Medicare, but that may soon change  Hearing health is a chronically overlooked aspect of our

    Read More
    Public
  • Gut happy! Medlab wants to change the way we treat depression

    There’s no doubt that we are living in extraordinary times. The COVID-19 pandemic has tested almost every aspect of our lives, our resilience, ability to organise and ability to adapt. With a drastic change in our way of living, the toll on our collective mental health has been profound. Beyond Blue estimates that over 3

    Read More
    Public
  • 4D Medical progresses with development of their dedicated lung diagnostics tech

    Every year traditional methods of lung diagnostics worldwide cost US $31 billion dollars. The arguably outdated technologies include the x-ray (invented in 1895), spirometry (invented in 1846) and CT (invented in 1971). Each has their own pros and cons, yet there remains a strong need for low dose, minimally  invasive, time efficient and cost effective

    Read More
    Public
  • No need to sugarcoat: Candy Club report sweet revenue increase

    Let’s face it. Candy and chocolate taste way WAY better than carrot sticks with hummus. And even if you swear by your rabbit food, the size of the global confectionery market speaks for itself. Estimated to be valued at USD $210.3 billion in 2019 and rising by a compound annual growth rate of 3.6%, the

    Read More
    Public
  • Would you like potato & gravy with that? Pure Foods Tasmania sales jump 70%

    Opening up the quarterly report from Pure Foods Tasmania (ASX: PFT), you are greeted by a stunning vista from where you’d rather be, good enough to rattle us locked down Victorians (please let us out please let us out please let us out).  I digress. Founded in 2015 to acquire, grow and develop premium food

    Read More
    Public
  • Tackling heart attacks with world first implantable monitoring device

    A heart attack can feel like literally anything. A sore arm, jaw pain, nausea… The list goes on. Difficulty in recognising a heart attack due to atypical symptoms increases for women, elderly and diabetics. The wide scope of symptoms can often result in costly emergency room visits and tests just to discover simple indigestion is

    Read More
    Public
  • Pup got itchy paws? You might want to remember this company’s name

    It wasn’t too long ago that I was in the shower, holding my squirming dog’s paws in a washing basket filled with an oatmeal concoction, whilst smearing peanut butter on the shower wall for her to lick. Why, you ask? Because my baby gets itchy paws (and I’m a great dog mom). Itchy paws and

    Read More
    Public
  • 1 in 4 babies in the US benefit from HeraMed’s pregnancy tech

    Medical data and technology company HeraMED (ASX: HMD) has today announced a partnership to accelerate their mission to revolutionise maternal care. The Company has entered into a paid pilot with Obstetrix Medical Group, one of the largest clinical providers in the US for both women’s and children’s health. Obstetrix, an affiliate of US $2.2 billion

    Read More
    Public
  • Diamonds are a pandemic’s best friend as Michael Hill sales sparkle

    Despite the enduring pandemic, lockdowns, restrictions and all the other crap that COVID has rained down upon us (I’m a VERY annoyed Melbournian this morning), retail has, for the most part, surprisingly stayed afloat, even thriving in some areas.  One of those areas is jewelry. Yep, diamonds remain a girl’s best friend, even when in

    Read More
    Public
  • Old trackies are comfy, old work ideas aren’t: how one company is revolutionising digital wellbeing

    Pyjama pant clad Zoom meetings are here to stay (I’m wearing spotty ones today, thanks for asking).  The new way we work is uncharted territory for many companies with managers forced to learn on the fly and adapt to the new normal. While we may be hitting our stride on the productivity side of things,

    Read More
    Public
  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication

    Fresh off their recent distribution success of their intravenous, non-opioid based pain medication, AFT Pharmaceuticals (ASX: AFP) has ticked another box announcing the receival of regulatory approval for another form of the drug. The oral liquid form of Maxigesic is a non-opioid based analgesic and extension of AFT’s patented Maxigesic family of medications. The oral

    Read More
    Public
  • World going nuts for Aussie almonds as supply squeeze beckons from California droughts

    Readers would know, from the numerous references in my articles, that I’m an oat latte girl. That being said, I do appreciate a good almond cap. But you didn’t come here to read about my coffee order (or maybe you did… If so we’ll get along swimmingly), you came to read about Select Harvests (ASX:

    Read More
    Public
  • PharmAust partners with the Walter and Eliza Hall Institute to expand COVID-19 research

    Forging ahead with their lead drug candidate, PharmAust (ASX: PAA) is expanding on their COVID-19 program. Their new angle is to investigate the effects of monepantel (MPL) on human T-lymphotropic virus-1 (HTLV-1) infections in partnership with leading biomedical research organisation, the Walter and Eliza Hall Institute (WEHI), based in Melbourne. The HTLV-1 virus is a

    Read More
    Public
  • A slice of the After-pie: NZ’s leading BNPL is making strides in responsible credit

    New Zealand’s leading BNPL provider, Laybuy (ASX: LBY) has reported an impressive year across the board, proving that there is space yet to grow in the seemingly saturated sector.  Since its inception in 2017, Laybuy has gone from strength to strength with a seemingly well timed entry into the BNPL market.  Laybuy is now recognised

    Read More
    Public
  • LBT Innovations to present clinical data at leading industry conference

    Adelaide-based medtech company LBT Innovations (ASX: LBT) is moving nicely along the path to commercialise their flagship product, presenting clinical data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held online over the weekend. The ECCMID represents the largest global conference for clinical microbiology and is a unique opportunity

    Read More
    Public
  • Could this pharma company hold the answer to overuse of opioids?

    Pain management is one of the most fascinating arms of medicine. Post-operative pain management, even more so. Practitioners must strike a balance to ensure that acute pain doesn’t turn into chronic pain, and that a patient’s dependence on analgesia is temporary. The many issues with opioid based pain medications are well documented and, with a

    Read More
    Public
  • Green with envy: RotoGro rolls up purchase order for medicinal cannabis facility

    Touted as a miracle cure for just about any ailment, medicinal cannabis has been an interesting point of contention in healthcare for years now. The media hype around the stuff has increased, patient demand has increased, and global production is booming (legally). Canadian based Wolf Island Cannabis is currently constructing a cannabis cultivation facility in

    Read More
    Public
  • Bionomics granted Fast Track approval from FDA to study PTSD drug

    Once upon a time, stress ensured our survival. When faced with a dangerous situation our body responds instantly- heart rate increases, blood pressure climbs and muscles tighten as the body prepares to deal with the bear/ exam you’ve been presented with.  In the modern world we are faced with a disproportionately higher amount of exams

    Read More
    Public
  • ResApp study data published, further confirms app’s efficacy

    Confirming the efficacy and broader potential of their smartphone-based diagnostic app, ResApp Health Limited (ASX: RAP) clinical data referenced in a top academic publication has validated their app’s accuracy for respiratory diagnostics. Data from their Breathe Easy adult clinical study has been published in a peer-reviewed Nature partner journal, npj Digital Medicine. The study looked

    Read More
    Public
  • Trading 101: Top tips for new traders

    If you enjoy being actively involved in your investments, you may be interested in trading. Traders take advantage of small price movements to turn a profit. Starting on the right track is about understanding both the fundamentals of trading, and you as a trader. The best investment you can make is in your education. Do

    Read More
    Public
  • Curing sickness with viruses: How Imugene is using oncolytic viruses to treat cancer

    Despite the many advances in cancer therapy, we still haven’t quite hit the nail on the head, with cancer still responsible for 12% of all deaths worldwide each year.  The advancement of cancer therapies and the growing body of research is impressive to say the least, yet cancer patients of today do not fare much

    Read More
    Public
  • IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float

    With ever increasing bodies of medical research and demand for early disease detection climbing, it’s high time that we rethink diagnostic testing. The trend of having to wait three days to see if your pee is free of nasties is fraught with administration challenges and can delay treatment. Spend time in any medical establishment and

    Read More
    Public
  • Truscreen expands market for real time digital diagnostic testing device

    Ahh the pap smear. The daunting, uncomfortable and downright annoying process of having a cervical swab taken to be tested for cancerous or precancerous cells, only to be repeated in 3-5 years time.  Despite being an important aspect of women’s health – COVID-19, uncomfortable gyno appointments, and misinformation means that booking in for that test

    Read More
    Public
  • Italian kids growing taller as NGS shake things up with milestone sales

    Addressing a chronically overlooked group in the nutritional supplement space is working out well for Nutritional Growth Solutions (ASX: NGS). The supplement company is focused on improving the health of children aged 3-12 years old who do not meet the criteria for growth hormone therapy. A group that has been long overlooked in terms of

    Read More
    Public
  • 9 year old me would have really wanted Spacetalk’s latest smartwatch

    As someone who was 9 years old once upon a time and desperate for a Gecko, Firefly or TicTalk, I’m pretty sure that Spacetalk’s (ASX: SPA) Adventurer would have sent my primary school self a bit nuts.  Like a kid-on-red-cordial nuts. The kids with the cool spy girl looking devices were the envy of my

    Read More
    Public
  • First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed

    Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir.   Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,

    Read More
    Public
  • Addressing growing healthcare demands with computer assisted medicine

    With more pressure than ever on the healthcare system, scalability is everything. How can we expand the system to meet increased demands by users? Pacific Knowledge Systems (ASX: PKS) is addressing this complex issue through their technology stack by providing software applications to better capture, apply and manage human expertise to enhance business performance and

    Read More
    Public
  • The blip in Cyclopharm’s plans for FDA approval

    There’s been a small bump in the road in Cyclopharm’s (ASX: CYC) plans to secure regulatory approval for Technegas™, their proprietary technology for lung imaging. Technegas™ comprises ultra-fine radioactive labelled carbon that is exposed to high heat to create a gas that can be inhaled by the patient. The gas allows for comprehensive imaging to

    Read More
    Public
  • Promising research for cancer diagnostic tests to be published

    Sadly, 1 in 7 women will be diagnosed with breast cancer at some stage in their life. That’s 1 in 7 mothers, daughters, aunties, girlfriends, wives, friends and nieces.  In the last 10 years, breast cancer diagnosis has increased by 36% and remains the second most common cause of death from cancer among females.  Health

    Read More
    Public
  • Promoting innovation: Empired wins multi-million dollar state government contract

    Digital technology transformation company Empired (ASX: EPD) does a lot. In a nutshell, the international tech company helps organisations transform and evolve through the best Microsoft technology enabling improved customer experiences, engaged staff and optimisation of cloud technologies. The Company has today announced that they have secured a $9 million contract with the Department of

    Read More
    Public
  • Respiri’s platform is taking asthma management beyond the clinic

    45% of people living with asthma have poor control of their condition which in turn, impacts their quality of life. Australia has one of the highest prevalence rates of asthma in the world with the disease affecting 2.7 million Australians, or 11% of the total population and costs us a massive $28 billion per year.

    Read More
    Public
  • Couch based online shopping sees Adairs bring forward Mocka settlement, set to re-invest

    Spending a mind numbing amount of time at home, as a locked down Victorian is wont to do sends you a bit loopy. It also might make that slightly squeaky dining chair drive you insane, or make you despise that old threadbare linen set you’ve had for years. Aussies have been feathering their nests with

    Read More
    Public
  • Over half a century since its launch, the contraceptive pill is getting a shake up

    Bloating, weight gain, mood swings, headaches. Just a handful of the not so lovely side effects bestowed upon women by the contraceptive pill. After half a century, I think we can all agree that the pill is long overdue for a shake up. With more women than ever increasingly aware of what they put into

    Read More
    Public
  • Paradigm’s study could give options to those with this rare incurable disease

    Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase 2 study of their flagship drug, pentosan polysulfate sodium (PPS) in patients with Mucopolysaccharidosis type VI (MPS VI). A big word to digest on a Friday morning, I know. The inherited disease is caused by

    Read More
    Public
  • Move over x-ray: 4D Medical’s respiratory scanning tech could be the new standard in imaging

    Invented in 1895 and becoming the standard in the early 1900s, the x-ray has long been the backbone of many medical diagnoses. The relatively unchanged technology has been commonplace for decades, but medtech company 4D Medical (ASX: 4DX) is rethinking the way we diagnose respiratory issues with their proprietary XV Technology™ and Permetium preclinical scanner. 

    Read More
    Public
  • Spray-on skin revenue exceeds initial forecasts

    The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter with the Company reporting strong revenue. The Company was founded to develop and commercialise the RECELL “spray-on skin” product, invented in Perth by Professor Fiona Wood. Professor Wood is a world renowned surgeon and researcher

    Read More
    Public
  • Goop might have been right…

    The keto diet is proving to be more than just another “It” diet touted by Goop with interesting research showing that it may have a place in cancer treatment. Eating a keto diet puts the body in a state of ketogenesis where instead of running off glucose based energy, the body is fueled by fats

    Read More
    Public
  • IPO Watch: Gefen Technologies to list on ASX with digital marketing platform for agents

    With initial plans to list in the Australian market last year furloughed by the pandemic, Israeli tech company Gefen Technologies is finally joining the dozen Israeli companies on the ASX, having closed their $25 million IPO at the end of last month. Israel is renowned for their ‘start up culture’, especially in tech, having produced

    Read More
    Public
  • How Noxopharm is overhauling the way we approach cancer treatment

    Traditional chemotherapy and radiotherapy have long been the standard of care for cancer treatment, but it’s no secret that there are numerous, debilitating side effects to a patient’s physical and mental health. Both are oftentimes ineffective with several cancers exhibiting poor responsiveness to traditional treatment.  Clinical-stage drug development company Noxopharm (ASX: NOX) is addressing this

    Read More
    Public
  • Epsilon to provide medicinal cannabis for clinical study in children

    A hot topic in medical research at the moment, medicinal cannabis studies are being carried out for seemingly any and all ailments. One such trial being run by the Murdoch Children’s Research Institute (MCRI) is extending efficacy studies of cannabidiol medicine to children with intellectual disability that exhibit severe behavioural problems. To facilitate these studies,

    Read More
    Public
  • Pharmaxis Investor Briefing – Cancer Treatment Clinical Trials

    On 4 June, 2021, Pharmaxis (ASX: PXS) hosted an investor briefing with CEO Gary Phillips to update investors on recent achievements and future plans, plus a Q&A with attendees. Topics discussed in the briefing and question time included: Clinical trial stage progress and timelines; Anticipated news flow for 2021-2022; Commercial opportunities being explored in collaborationRead More
    Public
  • Mad Paws to acquire Waggly Club, our office dog approves

    Feeding our office dog and many other pups Australia wide with their subscription meal service, Dinner Bowl, it’s safe to say Mad Paws (ASX: MPA) understands the subscription market. The Company has today announced the acquisition of one of Australia’s largest dog treats and toys subscription business, Waggly Club. Since its inception when founded by

    Read More
    Public
  • Strong sales continue for ZOLEO satellite messaging device

    Beam Communications (ASX: BCC) is enjoying the continued success of their satellite messaging device ZOLEO and has announced that they have received new orders for 22,000 of them. Sales have remained strong since ZOLEO’s launch in December 2019 with the device filling a previously unmet need for an affordable, compact and clever satellite messaging device.

    Read More
    Public
  • Could Dimerix be first to market with their innovative kidney disease drug?

    Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has today announced that their current Phase 3 drug for kidney disease has been awarded an Innovation Passport and the Innovative Licensing and Access Pathway (ILAP). The designation is awarded by the UK Medicines and Healthcare products Regulatory Agency and is designed to accelerate development of promising medicines to

    Read More
    Public
  • Openn Negotiation proptech IPO to bring transparency to real estate market

    The slimy sales tactics of prickly real estate agents may be in need of review with Australian property technology company Openn Negotiation set to debut on the ASX on Friday, 11 June.  A “proptech” company, Openn uses technology that aims to provide the best possible property sales outcomes for the seller, buyer and real estate

    Read More
    Public
  • Smart pain assessment app now used by more than half of Australia’s residential aged care providers

    Intelligent pain assessment company Painchek (ASX: PCK) is eager to become the new standard of care in aged care settings, today announcing that licensed agreements for their platform’s use now encompass 60% of Australian aged care providers. PainChek’s mobile based pain assessment tool uses AI and facial recognition software to objectively automate and quantify pain

    Read More
    Public
  • PharmAust receives ethics approval just in time for Big Freeze

    There is nothing fun about plunging into freezing cold ice water during a cold Melbourne winter. However, each year, bold celebrities participate in the annual ‘Big Freeze’ at the Melbourne Cricket Ground before the Melbourne vs Collingwood AFL clash on the Queen’s Birthday weekend.  The event, run by FightMND is designed to raise funds for

    Read More
    Public
  • ‘Working from home’ here to stay as productive Australians focus on wellbeing

    Among the many unknowns to emerge from the pandemic, the working from home phenomenon has plagued executive management but questions as to whether it would become the norm have been categorically answered with a resounding YES. Surveys have shown that working from home improves productivity and contributes to a better work life balance. Not having

    Read More
    Public
  • Genetic Technologies launches AI-based COVID Risk Test

    Personalised medicine is quickly becoming the new standard of healthcare thanks to the ease of genetic testing and technological advancements. Genetic Technologies (ASX: GTG) is pioneering a preventative, individualised approach to the COVID-19 pandemic through their experience in genomics and AI driven preventative health. Having already created genetic testing kits to predict breast and colorectal

    Read More
    Public
  • Avecho Biotechnology expands their proprietary drug delivery system to livestock

    Necessity is the mother of all invention, and seeing an opportunity, Avecho Biotechnology (ASX: AVE) has set about innovating a new livestock feed additive. The development of a new feed additive for animal use comes in anticipation of the European Union’s impending ban on livestock feeds with zinc oxide levels above a certain level. Zinc

    Read More
    Public
  • ZOLEO’s location tracking eliminates the need to drink piss, Bear Grylls thrilled

    Clunky satellite phones reminiscent of the bulky Nokia’s you’d carry around in the 90’s could soon become a thing of the past with Beam Communications’ (ASX: BCC) sexier tech offering. Beam’s joint venture company ZOLEO is well and truly changing the satellite phone game for adventurers the world over. The ZOLEO Satellite Communicator is an

    Read More
    Public
  • Food prototype success for Wide Open Agriculture’s plant-based proteins

    As someone with a penchant for oat milk lattes, Wide Open Agriculture’s (ASX: WOA) announcement today was music to my ears.  The regenerative food and agriculture company develops and distributes food products with a focus on conscious consumers.  They have today announced the results of a three month intensive research exercise conducted at Curtin University

    Read More
    Public
  • From A to B: Traffic Technologies is improving road safety in Victoria

    The removal of level crossings across Victoria has been a welcome change for Melbournians who have been reaping the benefits of smoother flowing traffic and less of that annoying, incessant ‘ding ding ding ding’ that we all despise. So far the Victorian Government’s “Big Build” program has seen the removal of 46 of 75 level

    Read More
    Public
  • 🎵 The knee bone’s connected to the… collagen rope device (?!)

    Regenerative medicine company Orthocell (ASX: OCC) has been granted patents from both China and Hong Kong for their proprietary novel CelGro® collagen rope device.  The addition of these two new patents means that the device is now patented across five jurisdictions including the US and Australia. The IP protection is integral to Orthocell’s commercialisation plans. 

    Read More
    Public
  • Investing 101: Five top tips for new investors

    We know that the share market can be confusing to navigate, and investing for the first time can be daunting. Before you start investing it’s important to understand some of the fundamentals of how the share market works as well as your preferences as an investor. We have put together our 5 top tips for

    Read More
    Public
  • Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status

    The commercialisation of osteoarthritis treatment ZILOSUL® has hit a hiccup in the United States with the US Food and Drug Administration (FDA) raising fresh questions to late-stage drug development company, Paradigm Biopharmaceuticals (ASX: PAR). The FDA response related to Paradigm’s application for Investigational New Drug status to be granted for their focus compound, Pentosan Polysulfate

    Read More
    Public
  • Zip expands to Europe and Middle East with further strategic acquisitions

    Zip Co’s (ASX: Z1P) global expansion plans are being realised with the Company today announcing the next steps for their push into overseas markets through the outright acquisitions of European BNPL provider Twisto Payments, and UAE-based BNPL leader Spotii Holdings. The move aligns with Zip’s strategic acquisitions plan. Both companies have been integrated into Zip’s

    Read More
    Public
  • Plenty of fish in the sea: Ridley to sell Tasmanian aquaculture facility

    Australia’s largest commercial provider of animal nutrition solutions, Ridley Corporation (ASX: RIC) has today announced the sale of their Tasmania extrusion and feed production facility. The sale of the facility to Skretting Australia will put $54.85 million into Ridley’s pocket and is expected to be finalised in the first half of FY22. The Company cites

    Read More
    Public
  • My Food Bag revenue increases as hungry Kiwis seek diet variety outside of ‘fush and chups’

    Contrary to popular belief, the Kiwis do not only eat ‘fush and chups’. Just like us Aussies, our neighbours do in fact eat a wide and varied diet not dissimilar to ours. My Food Bag (ASX: MFB) is one company delivering fresh ingredients across New Zealand in the form of meal kits. The Company has

    Read More
    Public
  • IPO Watch: Argenica Therapeutics developing drugs for brain recovery

    Every 19 minutes someone has a stroke. In 2019 that was 13 million people globally. During a stroke, the lack of oxygen caused by the blockage of blood vessels kills 1.9 million brain cells per minute. The medical interventional methods available to stroke patients are limited and focus on removing the clot chemically or mechanically.

    Read More
    Public
  • Applyflow sales rise as one-click apply emerges as the future of recruitment

    Many graduates lament over the old, clunky and annoying recruitment platforms and job boards that they are forced to trawl in the hopes of getting a foot in the door of their chosen industry. It’s no surprise that 60% of applications get abandoned due to complexity. It’s high time that something newer, streamlined and just

    Read More
    Public
  • Mosquitoes suck. Island Pharmaceuticals does not.

    Fun fact: The word mosquito actually translates to “little fly” in Spanish. Although you’re more likely to hear them called a whole host of profanities in many households. Little f***ers. If the blood sucking pests weren’t annoying enough, they carry diseases like dengue fever. An estimated 390 million people are infected with dengue each year.

    Read More
    Public
  • Nutritional Growth Solutions launches new snack bar to grow kids taller

    Ever noticed how the nutritional supplements that line the aisles of supermarkets and pharmacies are either for adults or children under the age of three? What about the kids in the middle? Key development continues well past the age of three and optimal nutrition plays a huge role in reaching developmental milestones. Addressing this long

    Read More
    Public
  • Medtech device sales a key step forward for LBT Innovations

    LBT Innovations (ASX: LBT) has this morning announced the sale of two of their AI pathology instruments. The Adelaide based med tech company is a leader in medical technology automation through the use of artificial intelligence.  Their flagship product is the APAS® Independence. The Automated Plate Assessment System (APAS®) technology integrates AI to automate culture

    Read More
    Public
  • BWX to acquire beauty and wellness online retailer Flora & Fauna

    The clean and natural beauty movement is well and truly mainstream. The rise of conscious consumerism has seen the natural beauty and wellbeing market grow by over 12% annually.  The proliferation of small brands that gain cult following are eroding the market share of the big players.  BWX (ASX: BWX) is a leading wellness business

    Read More
    Public
  • Strategic Elements: Homegrown innovation to quell invisible threats

    The threat of chemical, biological, radiological and nuclear (CBRN) attacks on both military and civilian populations is growing.  As if we didn’t already have enough to worry about. Anxiety riddled, chronic overthinkers and savvy investors alike will be glad to know that Strategic Elements (ASX: SOR) are working on solutions for autonomous sensing and search

    Read More
    Public
  • Lucapa found a 138 carat diamond, Danny Archer jealous

    Diamonds may very well be an investor’s best friend this morning with the Lucapa Diamond Company (ASX: LOM) announcing the finding of the 24th 100+ carat diamond from the Lulo alluvial diamond mine in Angola. The 138 carat stone brings the Company’s tally of 100+ carat diamonds found this year alone to 7. It is

    Read More
    Public
  • Delta Drone expands training operations, targets Namibia

    If you ever needed confirmation that we really are living in the future, all you need to do is look through the ASX listed tech companies and what they’re doing. The scope of our technological capabilities is downright impressive.  One company that might be of interest is Delta Drone International (ASX: DLT), a global Drones-as-a-Service

    Read More
    Public
  • IPO Watch: Australian Clinical Labs to list after successfully raising $408m

    In and amongst the slew of resource based IPOs vying for listing this month is Australian pathology company Australian Clinical Labs (Proposed ASX code: ACL).  The Company is hoping to join the likes of their ASX-listed competitors Sonic Healthcare (ASX: SHL) and Healius (ASX: HLS) later this month with an IPO Offer Price of $4

    Read More
    Public
  • How Incannex is helping you catch some zzz’s

    Unsurprisingly, four out of ten adults experience regular poor sleep. We all know the consequences of a bad night’s rest on our health, performance and mood, as well as the crippling caffeine addiction that develops. *Sips double shot oat milk latte*  People with Obstructive Sleep Apnoea (OSA) have it worse. OSA is characterised by partial

    Read More
    Public
  • Explain Like I’m 5: Trading vs Investing

    If you explore the world of the share market for more than two minutes you’re bound to come across the words “investing” and “trading”. But what is the difference between the two of them and how do you decide which is right for you? Let’s start with the basics. What is trading?  Trading involves frequent

    Read More
    Public
  • Archer Materials are progressing with their chips, not the salt and vinegar kind

    I’m not sure what’s harder- wrapping your head around what Archer Material’s (ASX: AXE) does, or comprehending the value of the market that they are tapping into. A market which currently sits at a whopping USD $400 billion per annum, and is forecast to reach over USD $1 trillion by 2030. Have I got your

    Read More
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment

    Jennie Young was one of the first patients to receive Veyonda, Noxopharm’s (ASX: NOX) proprietary drug. Administered on compassionate grounds, her doctors believe that she responded to it positively. She had leiomyosarcoma, a rare cancer that affects smooth muscle tissue. Soft tissue sarcomas like hers have limited treatment options with only 14% responding to chemotherapy. 

    Read More
    Public
  • Top of the class: Rhythm’s latest study results outperform the standard

    Colorectal cancer is the third most commonly occurring cancer in men, and the second in women. Yet every year 130 million people around the world between the ages of 50-74 remain unscreened. Rhythm Biosciences (ASX: RHY) are not complacent with that number and are working on an innovative solution to aid diagnosis of this major

    Read More
    Public
  • This company’s advanced 3D printing product could become industry standard

    From dental devices to jet engines, 3D printing is quickly becoming mainstream. Its use is moving well beyond prototyping and toys, towards industrial applications. Leading the way in the commercialisation of industrial 3D printers is AML3D (ASX: AL3), and their market update today proves that they plan on staying ahead of the game. The Company

    Read More
    Public
  • Will this sporting tech IPO be a Hit?

    Injury is inevitable in both elite and recreational sport. Most cuts, bruises, strains and tears can be remedied in a relatively short time frame with minimal ongoing issues. Traumatic brain injuries are quite the opposite. They can be debilitating, life altering and career ending. Following increased researcher interest and the findings of multiple studies, the

    Read More
    Public
  • Can Medibio’s software redefine mental health diagnostics?

    Mental illness will have an impact on 45% of Australians at some point in their lifetime. While the world is becoming increasingly aware of mental health conditions, little is being done to redefine the diagnostics. Currently, the gold standard in the diagnosis of mental illness is The Diagnostic and Statistical Manual of Mental Disorders (DSM5).

    Read More
    Public
  • Ingenia are not taking a break, so you can

    Australian’s are slowly pulling down their masks to embrace a new normal in the wake of the pandemic. Travel, at least domestically, is returning to pre-covid levels, a welcome change for those working in and around one of the hardest hit industries. Amongst those relieved companies is Ingenia Communities (ASX: INA). The Company is welcoming

    Read More
    Public
  • This company is really neat

    Craft beverage ‘accelerator’ Mighty Craft (ASX: MCL) has been getting Aussies tipsy on beer, spirits and now, whiskey.  The Company has today announced the appointment of two guys to their ‘Whiskey Acceleration Team’ (a trivia night team name winner for sure) whose job it is to get you buzzed.  Chris Malcolm and George Campbell are

    Read More
    Public
  • How three companies are collaborating to tackle an epidemic

    Three companies are joining forces to help tackle one of the most serious public health challenges of our time – the HIV/AIDS epidemic. Viatris and Atomo Diagnostics (ASX: AT1) have announced an agreement with Unitaid to increase accessibility of HIV self-testing in low-and middle-income countries (LMICs).  The announcement represents significant market expansion, with Unitaid committing

    Read More
    Public
  • Do you really own your shares?

    The global pandemic affected almost every aspect of modern life, and the stock market was no exception. The stock market crash early in 2020 saw an influx of retail investors and a huge increase in the number of accounts opened on trading apps. While investing is almost always a positive step towards financial freedom, experts

    Read More
    Public
  • Latitude IPO successful but how big will the exit selldown be?

    The saying ‘third time’s a charm’ rings true for financial services company Latitude (ASX: LFS) who finally made their entrance to the public market last week after cementing themselves as the biggest ASX float of 2021   This year’s offering marked Latitude’s third attempt at an IPO. Their first attempt was stalled in 2018 by investor

    Read More
    Public
  • PharmAust is putting a leash on canine cancer, and COVID-19

    From high rise city apartments to the rolling hills of the countryside, you’re likely to find a dog or two snuggled up on the living room couch. Studies have proven what us dog loving people already know- that the human-canine bond is special. Owning a dog reduces stress, alleviates anxiety and even can prolong your

    Read More
    Public
  • How 4DMedical is changing the medtech game post COVID

    While we are seemingly on the back-stretch of the COVID-19 pandemic, increased medical awareness has changed how we diagnose respiratory diseases with medtech company 4DMedical (ASX: 4DX) leading the charge. Their proprietary FDA/TGA approved, patented respiratory imaging platform, XV Technology turns sequences of x-ray images into four-dimensional, quantitative data to improve and accelerate diagnostic accuracy.

    Read More
    Public
  • High-touch, high-quality maternity care could soon become standard in major hospitals

    Bringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which

    Read More
    Public
  • New Anatara trial to tackle anxiety, stress and depression with diet supplement

    Working in conjunction with the CSIRO, Anatara Lifesciences (ASX: ANR) has received ethics approval to apply their diet supplement 3FDC to a new area of medicine, seeking to evaluate the compound’s effects in adults with moderate anxiety, stress and depression. 3FDC is one of the constituents of Anatara’s flagship supplement (GaRP) intended for the treatment

    Read More
    Public
  • Could Creso’s psychedelics solve Australia’s $10.6 billion problem?

    According to the Australian Department of Health, half of us will experience some form of mental illness in our lifetime. Treatment is somewhat limited to prescription medications and psychotherapy. However, the current mental health crisis has seen researchers and practitioners alike wondering- is there a better way to approach these frighteningly common conditions? Enter psychedelics,

    Read More
    Public
  • Millenials get happy! Alterra is making your smashed avo dreams come true

    Progressing their next-gen 300-hectare avocado project in Western Australia, sustainable agriculture specialist Alterra (ASX:1AG) could soon be extending the live-at-home lives of millenials that continue to prioritise smashed avo cafe breakfasts ahead of financial independence. The Company has released an update today on the progress of their flagship 300-hectare avocado project. The Carpenters Project, located

    Read More
    Public
  • The rising BNPL star giving Afterpay a run for their money

    Zip Co (ASX: Z1P) is nipping at the heels of Australian BNPL leader Afterpay (ASX: APT), based on today’s announcement of their Q3 results. Despite the pandemic, Zip has managed to maintain momentum and deliver strong results across Australian, New Zealand, UK and US markets bolstering itself as one of the fastest growing BNPL leaders.

    Read More
    Public
  • LBT Innovations sets sights on US healthcare market with AI-powered pathology

    Adelaide-based medical technology company LBT Innovations (ASX: LBT) is lining up distributors in the lucrative US healthcare market for their pathology screening tech which is driven by artificial intelligence to maximise testing throughput in labs, providing healthcare professionals with accurate results faster.    The Automated Plate Assessment System (APAS®) is a pathology AI device which automates

    Read More
    Public
  • Encouraging results from Recce Pharmaceuticals in fight against drug resistant bacteria

    As the world prepares for a myriad of drug-resistant bacteria following decades of over-prescribing and improper use of antibiotics, Recce Pharmaceuticals (ASX: RCE) has reported encouraging clinical results in response to multi drug resistant bacterial sinusitis infection. Following on from promising results observed in animal studies, a 59-year-old male was treated with the compound R327

    Read More
    Public